ChiCTR2600118038 版本V1.0 版本创建时间2026/02/01 16:19:53 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600118038 

最近更新日期:

Date of Last Refreshed on:

2026-02-01 16:19:48 

注册时间:

Date of Registration:

2026-02-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

内蒙古急性脑卒中医院间转运注册登记研究

Public title:

Inner Mongolia Acute Stroke Interhospital Transfer Registry

注册题目简写:

English Acronym:

研究课题的正式科学名称:

内蒙古急性脑卒中医院间转运注册登记研究

Scientific title:

Inner Mongolia Acute Stroke Interhospital Transfer Registry

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

崔宁 

研究负责人:

俞志鹏 

Applicant:

Ning Cui 

Study leader:

Zhipeng Yu 

申请注册联系人电话:

Applicant telephone:

+86 476 836 2431

研究负责人电话:

Study leader's
telephone:

+86 476 836 2431

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

619683050@qq.com

研究负责人电子邮件:

Study leader's E-mail:

yuzhipeng@bjmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

内蒙古自治区赤峰市红山区长青街152号

研究负责人通讯地址:

内蒙古自治区赤峰市红山区长青街152号

Applicant address:

No. 152, Changqing Street, Hongshan District, Chifeng City, Inner Mongolia Autonomous Region

Study leader's address:

No. 152, Changqing Street, Hongshan District, Chifeng City, Inner Mongolia Autonomous Region

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

赤峰市医院(首都医科大学宣武医院内蒙古医院)

Applicant's institution:

Chifeng Municipal Hospital(Xuanwu Hospital Inner Mongolia, Capital Medical University)

研究负责人所在单位:

赤峰市医院(首都医科大学宣武医院内蒙古医院)

Affiliation of the Leader:

Chifeng Municipal Hospital(Xuanwu Hospital Inner Mongolia, Capital Medical University)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

CK20251104

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

赤峰市医院伦理委员会

Name of the ethic committee:

Ethics Committee of Chifeng City Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-20 00:00:00

伦理委员会联系人:

孙显东

Contact Name of the ethic committee:

Xiandong Sun

伦理委员会联系地址:

内蒙古自治区赤峰市红山区长青街152号

Contact Address of the ethic committee:

No. 152, Changqing Street, Hongshan District, Chifeng City, Inner Mongolia Autonomous Region

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 180 4766 0444

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

赤峰市医院(首都医科大学宣武医院内蒙古医院)

Primary sponsor:

Chifeng Municipal Hospital(Xuanwu Hospital Inner Mongolia, Capital Medical University)

研究实施负责(组长)单位地址:

内蒙古自治区赤峰市红山区长青街152号

Primary sponsor's address:

No. 152, Changqing Street, Hongshan District, Chifeng City, Inner Mongolia Autonomous Region

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中华人民共和国

省(直辖市):

内蒙古自治区

市(区县):

赤峰市

Country:

CHINA

Province:

Inner Mongolia Autonomous Region

City:

Chifeng

单位(医院):

赤峰市医院(首都医科大学宣武医院内蒙古医院)

具体地址:

内蒙古自治区赤峰市红山区长青街152号

Institution
hospital:

Chifeng Municipal Hospital(Xuanwu Hospital Inner Mongolia, Capital Medical University)

Address:

No. 152, Changqing Street, Hongshan District, Chifeng City, Inner Mongolia Autonomous Region

经费或物资来源:

中央引导地方科技发展计划项目(2025ZY0028)资助

Source(s) of funding:

Supported by the Central Government Guides Local Science and Technology Development Program (2025ZY0028)

研究疾病:

急性缺血性卒中和自发性脑出血  

Target disease:

Acute Ischemic Stroke&spontaneous Intracerebral Hemorrhage

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

观察内蒙古自治区由PSC转诊至CSC的急性脑卒中患者在转诊全流程中的临床特征、治疗措施以及临床预后。  

Objectives of Study:

Observation of Clinical Characteristics, Treatment Measures, and Clinical Outcomes in Acute Stroke Patients Referred from PSC to CSC in the Inner Mongolia Autonomous Region Throughout the Entire Referral Process

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.临床诊断为AIS或sICH患者; 2.本次卒中发作至入院时间≤7天,若确切发病时间不详,则患者发病时间定义为“最后正常时间”; 3.患者首诊于PSC并计划转运至CSC; 4.受试者或其合法代理人签署知情同意书。

Inclusion criteria

1.Patients clinically diagnosed with AIS or sICH; 2.Time from this stroke onset to hospital admission is ≤7 days; if the exact onset time is unknown, the time of symptom onset shall be defined as the "last known well" time; 3.Patients first presenting to a PSC and planned for transfer to a CSC; 4.The subject or their legal authorized representative has signed the informed consent form.

排除标准:

Exclusion criteria:

None

研究实施时间:

Study execute time:

From 2026-01-30 00:00:00 To 2028-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-01 00:00:00 To 2028-05-31 00:00:00

干预措施:

Interventions:

组别:

急性脑卒中医院间转运注册登记观察组

样本量:

6000

Group:

Observation Group of Hospital-to-Hospital Transfer Registration and Monitoring for Acute Cerebral Stroke

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中华人民共和国

省(直辖市):

内蒙古自治区 

市(区县):

包头市 

Country:

CHINA

Province:

Inner Mongolia Autonomous Region

City:

Baotou

单位(医院):

包头市中心医院 

单位级别:

三甲 

Institution
hospital:

Baotou Central Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

卒中发作后第90+/-7天mRS评分分布

指标类型:

主要指标

Outcome:

Distribution of mRS scores at 90+/-7 days after stroke onset.

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卒中发作后第90+/-7天mRS评分0-1分患者比例

指标类型:

次要指标

Outcome:

Proportion of patients with mRS score 0-1 at 90+/-7 days after stroke onset

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卒中发作后第90+/-7天mRS评分0-2分患者比例

指标类型:

次要指标

Outcome:

Proportion of patients with mRS score 0-2 at 90+/-7 days after stroke onset

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卒中发作后第90+/-7天mRS评分0-3分患者比例

指标类型:

次要指标

Outcome:

Proportion of patients with mRS score 0-3 at 90+/-7 days after stroke onset

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

24小时NIHSS评分相比基线的变化

指标类型:

次要指标

Outcome:

Change in NIHSS score at 24 hours compared to baseline

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

7+/-2天/出院(以先发生时间为准)时NIHSS评分相比基线的变化

指标类型:

次要指标

Outcome:

Change in NIHSS score at 7+/-2 days/hospital discharge (whichever occurs first) compared to baseline

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

转诊决策(签署转诊知情同意时间)至从PSC出发时间(min)

指标类型:

次要指标

Outcome:

Time from referral decision (time of signing transfer informed consent) to departure from PSC (min)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

转诊决策至抵达CSC时间(min)

指标类型:

次要指标

Outcome:

Time from referral decision to arrival at CSC (min)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

发病-溶栓时间(min)(发病时间定义为最后正常时间)

指标类型:

次要指标

Outcome:

Onset-to-thrombolysis time (min) (onset time is defined as last known well)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

发病-穿刺时间(min)

指标类型:

次要指标

Outcome:

Onset-to-puncture time (min)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

发病-再通时间(成功再通定义为eTICI≥2b)(min)

指标类型:

次要指标

Outcome:

Onset-to-recanalization time (successful recanalization defined as eTICI ≥ 2b) (min)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

入院(患者接受静脉溶栓的医院)-溶栓时间(min)

指标类型:

次要指标

Outcome:

Door-to-needle time (min) (at the hospital where the patient received intravenous thrombolysis)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

入院(CSC)-穿刺时间(min)

指标类型:

次要指标

Outcome:

Door-to-puncture time (min) (at CSC)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

入院-再通时间(成功再通定义为eTICI≥2b)(min)

指标类型:

次要指标

Outcome:

Door-to-recanalization time (successful recanalization defined as eTICI ≥ 2b) (min)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

穿刺(CSC)-再通时间(成功再通定义为eTICI≥2b)(min)

指标类型:

次要指标

Outcome:

Puncture-to-recanalization time (successful recanalization defined as eTICI ≥ 2b) (min)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卒中发作后第90±7天mRS评分分布

指标类型:

主要指标

Outcome:

Distribution of mRS scores at 90±7 days after stroke onset.

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卒中发作后第90+/-7天mRS评分0-1分患者比例

指标类型:

次要指标

Outcome:

Proportion of patients with mRS score 0-1 at 90+/-7 days after stroke onset

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卒中发作后第90+/-7天mRS评分0-2分患者比例

指标类型:

次要指标

Outcome:

Proportion of patients with mRS score 0-2 at 90+/-7 days after stroke onset

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卒中发作后第90+/-7天mRS评分0-3分患者比例

指标类型:

次要指标

Outcome:

Proportion of patients with mRS score 0-3 at 90+/-7 days after stroke onset

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早期神经功能恶化(24小时内NIHSS增加≥4分)

指标类型:

次要指标

Outcome:

Early neurological deterioration (increase in NIHSS score ≥ 4 points within 24 hours)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

7+/-2天/出院(以先发生时间为准)时NIHSS评分相比基线的变化

指标类型:

次要指标

Outcome:

Change in NIHSS score at 7+/-2 days/hospital discharge (whichever occurs first) compared to baseline

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院期间神经功能恶化比例(NIHSS评分增加≥4分和/或格拉斯哥昏迷量表评分下降>1分)

指标类型:

次要指标

Outcome:

Proportion of neurological deterioration during hospitalization (increase in NIHSS score ≥ 4 points and/or decrease in Glasgow Coma Scale score > 1 point)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血肿扩大率(基线CT至随访CT期间血肿体积增加>33%和/或>6ml)

指标类型:

次要指标

Outcome:

Rate of hematoma expansion (increase in hematoma volume > 33% and/or > 6 ml from baseline CT to follow-up CT)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-01 16:19:48